Double arm Clinical trial to evaluate the role of basti karma and virechan karma in hyperuricemia. - NI

Ayurvedic and Unani Tibbia College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•Patients attending out patient department with Sr. Uric Acid levels greater than 7.0mg/dl will be
•enrolled in the study.

•Patients who are contraindicated for Basti karma will not be included in Group A and for those who are contraindicated for Virechan karma will not be included in Group B. For both groups: Rectal prolapse, Fever, Pregnant and lactating mothers etc. For Group A: Udar rog, intestinal perforation, intestinal obstruction etc. For Group B: Loss of bowel control, atisara(diarrhea) etc
•Known case of Rheumatoid Arthritis, Psoriatic Arthritis
•Patients with renal or hepatic impairment (Sr creatinine greater than 1.8mg/dl along with Sr Urea greater than 60 mg/dl, SGOT and SGPT greater than Five times of upper limit Patients having LDL and Triglycerides greater than two times of upper limit
•Patients with co-morbid conditions such as Hypertension grade 2 greater than equal to 160/100mm of Hg) or more, Diabetes Mellitus (having HbA1c greater than 7.5% with or without hyperglycemicmedications
•Patients who are on anti tubercular or anti retroviral medication
•Patients requiring emergency treatment

发起方

Ayurvedic and Unani Tibbia College and Hospital